Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…
Having eschewed any late-stage moves in Nash, Novo Nordisk needs its established diabetes drug Ozempic to prove it has a place in the liver disease.
Yesterday’s clinical study success has underlined VTV's status as a small-cap bet on Alzheibetes.
January saw Aimmune receive an FDA approval for Palforzia, a first for peanut allergy, alongside decisions for Blueprint Medicines and Horizon Therapeutics.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Enhertu gets an early thumbs up from the FDA – now decisions are due for Epizyme’s tazemetostat and Novo Nordisk's Rybelsus and Ozempic.
A day after seladelpar is canned over toxicity fears elafibranor passes a safety review, but should Genfit holders worry all the same?